Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia

Annals of Hematology

Volumn 95, Issue 6, 2016, Pages 1001-1009

  Hahn Ast, C ^a   Felder, L ^a   Mayer, K ^a   Muckter S ^a   Ruhnke, M ^b   Hein, R ^c   Hellmich, M ^c   Schwab, K ^a   Rachow, T ^d   Brossart, P ^a   von Lilienfeld Toal, M ^a,d,e  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Paracelsus Klinik Osnabruck   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Antifungal prophylaxis; Antimycotic chemotherapy; Empirical antifungal therapy; Febrile neutropenia; Invasive fungal infections

Indexed keywords

ANTINEOPLASTIC AGENT; CASPOFUNGIN; ITRACONAZOLE; POLYENE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIFUNGAL PROPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SURVIVAL; DRUG DELIVERY SYSTEM; EMPIRICAL RESEARCH; MIDDLE AGED; MORTALITY; POST EXPOSURE PROPHYLAXIS; PROCEDURES; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

AGED; ANTIFUNGAL AGENTS; COHORT STUDIES; DRUG DELIVERY SYSTEMS; EMPIRICAL RESEARCH; FEBRILE NEUTROPENIA; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84961618717     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2630-1     Document Type: Article

References (26)

1. Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21:4615–4626
2. Ziakas PD, Kourbeti IS, Voulgarelis M, Mylonakis E (2010) Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clin Ther 32:2316–2336
3. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359
4. Buchheidt D, Böhme A, Cornely OA, Fätkenheuer G, Fuhr HG, Heussel G, Junghanss C, Karthaus M, Kellner O, Kern WV, Schiel X, Sezer O, Südhoff T, Szelényi H, Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) (2003) Diagnosis and treatment of documented infections in neutropenic patients—recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S127–132
5. Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32–S37
6. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751
7. Marchetti O, Cordonnier C, Calandra T (2007) Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer 5(2):32–42
8. Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, Heussel CP, Kahl C, Kiehl M, Lorenz J, Hof H, Mattiuzzi G (2009) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 45:2462–2472
9. Goldstone AH, O'Driscoll A (1994) Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 14(Suppl 5):S15–17
10. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111
11. Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M (2006) A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 34:118–126
12. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771
13. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J, National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234
14. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402
15. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113–122
16. Hahn-Ast C, Glasmacher A, Mückter S, Schmitz A, Kraemer A, Marklein G, Brossart P, von Lilienfeld-Toal M (2010) Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 65:761–768
17. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821
18. Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF (2014) Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123:4027–4036
19. Schlenk RF, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Kindler T, Lübbert M, Martin H, Salih HR, Kuendgen A, Horst HA, von Lilienfeld-Toal M, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Mergenthaler HG, Salwender H, Rummel MJ, Raghavachar A, Benner A, Schlegelberger B, Ganser A, Döhner H (2011) All-Trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia—results of the AMLSG 07–04 randomized treatment trial. Blood (ASH Annual Meeting Abstracts) 118:80
20. von Lilienfeld-Toal M, Hahn-Ast C, Kirchner H, Flieger D, Dölken G, Glasmacher A (2007) A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy. Haematologica 92:1719–1720
21. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IGH (1999) Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42:591–600
22. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive Aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604–1610
23. Schulz B, Weber K, Radecke C, Scheer C, Ruhnke M (2009) Effect of different sample volumes on the DNA extraction of Aspergillus fumigatus from whole blood. Clin Microbiol Infect 15:686–688
24. Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Matturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foà R, Micozzi A (2012) Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 97:560–567
25. Egerer G, Geist MJ (2011) Posaconazole prophylaxis in patients with acute myelogenous leukaemia—results from an observational study. Mycoses 54(Suppl 1):7–11
26. Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA (2010) Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 65:1466–1471